More Potential Catalysts: Two Major Analyst Price Targets
Back on April 28th, Brookline Capital Management analyst Sally Yanchus tagged DARE with a $7.50 price target.
Additionally, she provided a "BUY" rating.
Last month, Roth Capital analyst Zegbeh Jallah initiated coverage with a "BUY" rating and a price target of $7.00.
From Friday's close of $1.04, DARE is providing potential upside of 621% to the $7.50 target and potential upside of 573% to the $7.00 target.
Now, I'm not saying that DARE is going to go surging over 500% today, but the potential upside based on these analyst recommendations is massive.
Find the price targets here.
Two More Potential Catalysts - Recent News Hits The Wire
Daré Bioscience Receives $0.9Mn Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)
Contraceptive Program Supported by approximately $20.5Mn in Grant Funding from the Bill & Melinda Gates Foundation to Date
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9Mn in funding under the current grant from the Bill & Melinda Gates Foundation. The grant payment will support ongoing development activities for Daré’s investigational user-controlled, long-acting reversible contraceptive (UC-LARC), DARE-LARC1. Development of DARE-LARC1 has been supported by approximately $19.5Mn in grant funding from the foundation prior to this most recent disbursement.
The technology underpinning DARE-LARC1 is designed to store and precisely deliver therapeutic doses over months or years in a single implant and was originally developed at the Massachusetts Institute of Technology (MIT) by renowned researchers Robert Langer, Ph.D. and Michael J. Cima, Ph.D.
“We believe the non-dilutive funding support from the foundation for the development of DARE-LARC1 is a clear validation of the unmet need in the long-acting, reversible contraceptive, or LARC, category,” said Sabrina Martucci Johnson, President & CEO of Daré Bioscience. “LARCs are one of the most successful innovations in contraception, due to their exceedingly high effectiveness rates and duration of protection ranging from 3 to 10 years. The current FDA-approved LARCs require physician insertion and subsequent removal procedures for return to fertility, which can be a deterrent for women who know they will likely want to pause their contraception at some point during a typical 3 to 10 year implant duration. Our DARE-LARC1 program seeks to improve upon this product profile by providing a user-controlled LARC with a comparably high level of contraceptive effectiveness that will not require a woman to undergo procedures to remove and re-insert the device when she wants to return to fertility and, subsequently, when she wants resume contraception.”
DARE-LARC1 is a preclinical stage implantable contraceptive product that is designed to deliver the benefits of traditional long-acting, reversible contraceptive products with the added flexibility of wirelessly controlling the duration of drug release based on individual user needs. The implant is intended to be operated by the user to deliver medication on a pre-determined schedule that can be activated or deactivated wirelessly, as required to provide contraceptive protection or enable her to return to fertility. This grant payment will support critical ongoing preclinical activities necessary to advance the program to the next stage of development.
Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff
SAN DIEGO and ANN ARBOR, Mich., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract research, development, and manufacturing organization specializing in chemical analysis and product development, today announced that the companies have signed an agreement under which Avomeen will provide contract product development laboratory services with a team specifically assembled to support the advancement of Daré’s innovative pipeline of investigational products designed to address persistent unmet needs in women’s health. The unique partnership model is intended to enable Daré to leverage Avomeen’s scientific expertise, including advanced instrumentation and development techniques, and accelerate development of key programs in a capital-efficient manner.
Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline. Central to the collaboration is Avomeen’s ability to develop customized protocols, test methods, and formulations with processes tailored to unique product requirements and specifications. This capability aligns with Daré’s portfolio of potential first-in-category products, which often require a customized approach to method development.
“One of the clear goals of this partnership is to leverage Avomeen’s ingenuity and expertise in biopharmaceutical development to support our clinical program initiatives in women’s health,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Avomeen has a proven track record and impressive regulatory accreditations combined with cutting-edge technological capabilities that we believe will enable us to accelerate development activities across our portfolio. Further, we believe that the partnership agreement will result in greater efficiencies and savings in our research and development expenditures.”
Under the terms of the agreement, Avomeen will be Daré’s preferred provider of product development laboratory services for an initial three-year period, provided that Avomeen has the expertise, resources and availability to perform the services that Daré requires. In exchange for receiving that exclusive service provider status, Avomeen will assemble operating and oversight teams committed to the partnership and provide a preferred discounted pricing structure and, if volume reaches designated levels, will also provide scientific personnel dedicated exclusively to supporting Daré’s development programs covered by the agreement.
“Avomeen is excited about this partnership and is well positioned to augment the existing clinical technical and regulatory competencies at Daré,” said Mark Harvill, CEO of Avomeen. “We have been able to apply our novel scientific and technical solutions to Daré’s diverse portfolio, in large part due to the collaborative approach that Daré implements with its development partners like Avomeen.”
Top 5 Potential Catalysts To Research On DARE
1. Signed License Agreement With Bayer
2. $7.50 Analyst Price Target From Brookeline Capital Management
3. $7.50 Analyst Price Target From ROTH Capital
4. Recent grant funding from the Bill & Melinda Gates Foundation
5. Forming A Strategic Partnership With Avomeen
Coverage is officially initiated on DARE immediately.